Clinaptis Research

Dyne (DYN): HARBOR Cut the Price. Didn’t Lower the Bar for ACHIEVE-REC DM1

Thu, 08 Oct 2026 00:00:00 GMT

Novartis Phase 3 HARBOR miss hit Dyne’s valuation though we estimate $1.5B NPV is still attributable to DM1. We remain cautious (41% odds) into Q1 2027 Achieve-REC readout of Z-basivarsen.

XBI Short Interest: Still Not Covering [Aug 15 to Sep 15]

Fri, 02 Oct 2026 00:00:00 GMT

The $1–5B bear book kept adding through an August rally and a September decline: builds outran covers 24 to 17, then 27 to 7.

Eli Lilly’s Eloralintide + Tirzepatide: Stronger Parts, Not Synergy in Diabetes

Wed, 30 Sep 2026 00:00:00 GMT

Lilly’s 10-arm eloralintide + tirzepatide Phase 2 in type 2 diabetes reads out at EASD. Our bar: 12–14% placebo-adj. weight loss at go-forward dose; <11% disappoints. GI burden decides market.

Praxis (PRAX): EMERALD Doesn't Need Another 53% Seizure Reduction

Tue, 29 Sep 2026 00:00:00 GMT

EMERALD needs roughly 22.5% placebo-adjusted efficacy across broad DEE, not another EMBOLD-like 53%; who responds and how the primary analysis measures the mixture determine the franchise value.

Viking Therapeutics (VKTX): The Schedule Held; the Price Ran Ahead

Wed, 23 Sep 2026 00:00:00 GMT

VK2735's maintenance data strengthen the subcutaneous thesis. We assess the value added against VKTX's $1.25 billion rally.

Agios (AGIO): Mitapivat in Sickle Cell Disease — REIGNITE Is Not the Hard Part

Tue, 22 Sep 2026 00:00:00 GMT

Our work supports ~72% predictive PoS for Phase 3 REIGNITE. The harder question is whether mitapivat can capture enough SCD share to justify $33/sh.

Rhythm (RYTM): The Price of a Strong Rare-Obesity Launch

Sat, 19 Sep 2026 00:00:00 GMT

The acquired-HO launch is strong, but our cohort model implies ~$63 per share at Base and shows how much patient capture, persistence and post-2034 durability the ~$8B valuation already requires.

Lp(a) After the First Failure: Repricing OCEAN(a)

Mon, 14 Sep 2026 00:00:00 GMT

The dual endpoint miss puts null Lp(a) biology near 19% and reprices OCEAN(a) from 87.9% pre-HORIZON to ~65–72% statistical success.

XBI Short Interest: The Approval They Shorted Anyway

Tue, 08 Sep 2026 00:00:00 GMT

In 1H August, 38 of 60 core XBI names added to shorts while aggregate exposure rose just 0.7%—broad builds offset by a few catalyst-driven covers.

Definium, Psychedelics & the Price of Replication in Anxiety (GAD)

Sat, 05 Sep 2026 00:00:00 GMT

Phase 3 PANORAMA in GAD is overwhelmingly likely to succeed statistically. But HAM-A efficacy magnitude matters non-linearly: the value curve steepens around the ~4-point differentiation threshold.

Corbus (CRBP): CANYON-1 and the Twenty-Year Search for a Peripheral CB1 Window

Sun, 30 Aug 2026 00:00:00 GMT

The bar is ≥5% Week-12 weight loss without a CNS signal. Clear it, and CRB-913 becomes an investable peripheral-CB1 asset worth ~$16.5/share versus ~$11 today.

Annexon: ARCHER II Is More Than a Replication Bet in GA

Wed, 26 Aug 2026 00:00:00 GMT

ARCHER II can survive heavy regression of the Phase 2 GA effect — RR ~0.5–0.6 still leaves a viable Phase 3, with replicated visual functional benefit offering genuine differentiation in GA

Kodiak's DAYBREAK: Likely to Work, Less Likely to Matter

Sat, 22 Aug 2026 00:00:00 GMT

Non-inferiority remains the base case (~63%) — but the pass is more likely to be commercially thin than differentiated, and that is what the stock trades on.

XBI: What Survived July's Short Retreat

Sun, 16 Aug 2026 00:00:00 GMT

XBI Short Interest Monitor · $1–5B cohort · July 31, 2026 settlement

Celldex: A Positive CSU Readout May Not Be Enough

Sat, 15 Aug 2026 00:00:00 GMT

The p-value looks de-risked. Valuation hinges on whether complete response (CR) looks more like remibrutinib (~28–31%) or clears Xolair’s historical ~34–44% range.

Praxis: Odds Favor Ulixacaltamide Approval in ET, but…

Tue, 11 Aug 2026 00:00:00 GMT

The regulatory case looks settled. The commercial case does not: patients × price × persistence now decide whether today's valuation holds.

Structure Therapeutics: Is Aleniglipron Really Best-in-Class?

Sat, 08 Aug 2026 00:00:00 GMT

Aleniglipron's 16.3% WL headline restates to ~10–11pp on the basis FDA now requires — a real edge in. oral GLP-1 class, not an established best-in-class gap.

Viking Therapeutics (VKTX): Repricing VK2735

Tue, 04 Aug 2026 00:00:00 GMT

Separating the SC valuation floor from the unresolved oral opportunity through a reverse-solve valuation framework and a ~608,000-patient crossover analysis.

Acadia's Alzheimer's Psychosis Bet: Direction Is Priced, Resolution Is Not

Wed, 29 Jul 2026 00:00:00 GMT

We're constructive into Sep/Oct: ~70–80% odds of success, and we like the setup — the alpha's in the magnitude: fade a thin print, add on a strong one.

Lean Mass: Selectivity Is the Trap

Mon, 20 Jul 2026 00:00:00 GMT

Selectivity makes apitegromab's lean-mass result (1.9 kg preserved vs. placebo) the cleanest in obesity — and the why exactly why it hasn't proven mass becomes function.

BIIB Alzheimer’s: CELIA Validated Tau, Not the Clinical Effect Size

Thu, 16 Jul 2026 00:00:00 GMT

The reported 26% slowing likely overstates the underlying effect. That does not mean Biogen chose the wrong dose.

Where Bears Are Still Building In XBI

Tue, 14 Jul 2026 00:00:00 GMT

Why crowded shorts have already priced the bear case — and where the marginal short is actually arriving.

MPLT: Antipsychotic Efficacy Is the Floor. Tolerability Is the Trade Into Ph2 Readout

Thu, 09 Jul 2026 00:00:00 GMT

Cobenfy proved dual M1/M4 agonism works. Ph2 ZEPHYR's job is showing whether ML-007C-MA's PK-tuned tolerability edge is real — which is why the AE table, not the PANSS table, carries the real signal.

Milvexian: AF and Stroke Indications Should Be Valued Separately

Tue, 07 Jul 2026 00:00:00 GMT

A quantitative reconstruction of BMS/J&J's Phase 3 dose-selection framework, using PK/PD modeling to independently estimate each indication's probability of success.

AMLX: Ph3 PBH Readout Less Binary Than It Looks

Thu, 02 Jul 2026 00:00:00 GMT

Three independent statistical frameworks suggest 3Q26 LUCIDITY readout is materially more derisked than prevailing investor confidence implies.

uniQure’s AMT-130: The FDA Changed Its Mind. The Data Didn’t.

Tue, 30 Jun 2026 00:00:00 GMT

Projecting Four-Year cUHDRS and TFC Outcomes Ahead of AMT-130’s Q3 2026 BLA, Confirmatory Trial, and Commercial Launch in Huntington's Disease (HD)

When 45% Isn't Enough: Rethinking Disease Modification in IgAN

Sun, 28 Jun 2026 00:00:00 GMT

Reviewing Vera's Atacicept & Why the Next IgAN Winners Will Be Decided by Residual Disease Burden.

IONS Drew First Blood. SHASTA-3/4 Is Arrowhead’s Turn

Thu, 25 Jun 2026 00:00:00 GMT

Tryngolza’s approval changes the question ahead of SHASTA-3/4. The Street will focus on headline TG reduction; we think the real readout is threshold crossing below 500 mg/dL.

The Rise of Mini-Pharma: Why Commercial Concentration Is Replacing Platform Breadth

Tue, 23 Jun 2026 00:00:00 GMT

Concentration, commercial proof, and the rise of biotech’s new operating model.

Axsome (AXSM): $250 Is the Problem

Sat, 20 Jun 2026 00:00:00 GMT

Auvelity is a real franchise. The ADA launch is real optionality. Neither justifies $250.

Orexin and Narcolepsy

Fri, 12 Jun 2026 00:00:00 GMT

What the first orexin agonist approval in Narcolepsy Type I (NTI) actually validates.

GLP-1s Solved Efficacy. They Haven't Solved Obesity

Mon, 08 Jun 2026 00:00:00 GMT

The two-leak problem in the obesity treatment funnel — and what oral drugs can and cannot fix.

The MASH Bridge Trap

Wed, 03 Jun 2026 00:00:00 GMT

Why Madrigal's Rezdiffra Market Is Smaller Than the Model

Pancreatic Cancer Had No Druggable Target. Now It Does

Mon, 01 Jun 2026 00:00:00 GMT

Daraxonrasib in 2L PDAC: When the Data Actually Deliver

Retatrutide’s 28%: The PCSK9 Mistake

Sat, 23 May 2026 00:00:00 GMT

Why Superior Efficacy Doesn't Always Win the Market

XBI 2026: What the Tape Is Rewarding vs. Punishing

Wed, 20 May 2026 00:00:00 GMT

Why 2026 Became a Market for Visibility, Reinforcement, and Shorter Timelines

Obesity: Leaders De-risked, Debate Shifting Toward Market Structure

Mon, 18 May 2026 00:00:00 GMT

Obesity Is Evolving From a Drug Category Into Metabolic Infrastructure

Functional Endpoints and the New CNS Market Structure

Sun, 17 May 2026 00:00:00 GMT

Functional Endpoints, Persistence Economics, and Signal Interpretation in Modern Neuropsychiatry